在三阴性乳腺癌中准分子标的PROTACs
Gyas Khan1, Sarfaraz Ahmad2, Md Sadique Hussain3
1Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
Current medicinal chemistry
|September 5, 2025
概括
通过降解关键基蛋白质,基蛋白向细胞 (PROTACs) 为三阴性乳腺癌 (TNBC) 提供了一种新的治疗策略. 这种方法有望克服耐药性并改善患者的治疗结果.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 三重阴性乳腺癌 (TNBC) 缺乏向治疗,依赖于常规治疗,但具有耐药性和毒性等局限性.
- 目前用于TNBC的治疗方法,包括化疗和免疫疗法,在有效性和患者安全性方面面临重大挑战.
- 针对蛋白质分解的仿真体 (PROTACs) 代表了通过无处不在蛋白质酶系统降解致病蛋白质的新疗法.
研究的目的:
- 审查PROTACs在治疗三阴性乳腺癌中的应用.
- 确定TNBC中PROTAC的关键分子标,包括BET蛋白,SRC-1,PARP1,FAK,c-Myc和CDK.
- 评估PROTACs在克服耐药性和增强TNBC治疗功效方面的潜力.
主要方法:
- 专注于PROTAC技术及其在TNBC研究中的应用的文献综述.
- 在临床前TNBC模型中识别特定的PROTAC分子及其向蛋白.
- 对研究PROTACs对癌症进展,耐药性和蛋白质降解的影响的分析.
主要成果:
- 针对TNBC中的关键瘤蛋白,例如BET蛋白,SRC-1,PARP1,FAK,c- Myc和CDK.
- 特定的PROTACs如BETd-246,ND1-YL2和pal- pomPROTACs在减少TNBC进展和转移方面表现出有效性.
- 针对EZH2,AR和TRIM24的PROTAC突出显示了这种治疗策略在TNBC中的多功能性.
结论:
- 对于开发更有效,更有针对性的三阴性乳腺癌治疗, PROTAC 显著有前途.
- 在优化PROTAC的药理动力学,稳定性,生物可用性,选择性和最小化毒性方面仍然存在挑战.
- 在PROTAC设计和正在进行的临床研究方面取得的进展表明,TNBC患者的生存率和生活质量有可能得到改善.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K